Antibacterial activity of LCB01-0062, a novel oxazolidinone

被引：7

作者：

Jung, Sung-Ji ^{[1
]}

Yun, Na-Rae ^{[1
]}

Park, Hee Soo ^{[1
,2
]}

Lee, Hyun-Hee ^{[1
]}

Jeong, Ji-Woong ^{[1
]}

Kim, Yong-Zu ^{[3
]}

Cho, Young-Lak ^{[3
]}

Kwak, Jin-Hwan ^{[1
]}

机构：

[1] Handong Global Univ, Sch Life Sci, Pohang 791708, South Korea

[2] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA

[3] LegoChem Biosci Inc, Taejon 305811, South Korea

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2012年 / 40卷 / 06期

关键词：

LCB01-0062; Oxazolidinone; MIC; Time-kill; Systemic infection; ANTIBIOTICS; RESISTANT;

D O I：

10.1016/j.ijantimicag.2012.07.017

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

LCB01-0062, a novel oxazolidinone, has potent antibacterial activity against clinical isolates of Gram-positive bacteria. The in vitro activity of LCB01-0062 was compared with that of linezolid, oxacillin, erythromycin, ciprofloxacin, vancomycin and quinupristin/dalfopristin. Among the tested agents, LCB01-0062 showed the most potent antibacterial activity against meticillin-resistant Staphylococcus aureus, meticillin-resistant coagulase-negative staphylococci and vancomycin-resistant enterococci. LCB01-0062 was 4-8-fold more active than linezolid, the first oxazolidinone drug, against Gram-positive bacteria. The time-kill curves of LCB01-0062 were analysed at concentrations of 0.5x, 1x, 2x, 4x and 8x the minimum inhibitory concentration against S. aureus strains. LCB01-0062 showed bacteriostatic activity during 24 h. LCB01-0062 was also more effective than linezolid against S. aureus in a systemic mouse model of infection. (C) 2012 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：539 / 543

页数：5

共 13 条

[1]

[Anonymous], 2012, METHODS DILUTION ANT

[2] Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid [J].

Babcock, HM ;

Ritchie, DJ ;

Christiansen, E ;

Starlin, R ;

Little, R ;

Stanley, S .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (09) :1373-1375

[3]

Bliss CI, 1985, STAT BIOASSAY

[4]

Clinical Laboratory Standards Institute, 1999, METH DET BACT ACT AN

[5] Oxazolidinone antibiotics [J].

Diekema, DJ ;

Jones, RN .

LANCET, 2001, 358 (9297) :1975-1982

[6] Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit [J].

Ippolito, Joseph A. ;

Kanyo, Zoltan F. ;

Wang, Deping ;

Franceschi, Francois J. ;

Moore, Peter B. ;

Steitz, Thomas A. ;

Duffy, Erin M. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (12) :3353-3356

[7] Antibacterial resistance worldwide: causes, challenges and responses [J].

Levy, SB ;

Marshall, B .

NATURE MEDICINE, 2004, 10 (12) :S122-S129

[8] The need for new antibiotics [J].

Livermore, DM .

CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 :1-9

[9] Update on the safety of linezolid [J].

Metaxas, Eugenios I. ;

Falagas, Matthew E. .

EXPERT OPINION ON DRUG SAFETY, 2009, 8 (04) :485-491

[10] Discovering new antimicrobial agents [J].

Moellering, Robert C., Jr. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 37 (01) :2-9

← 1 2 →